$228 Million is the total value of Prosight Management, LP's 38 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MLND | Exit | MILLENDO THERAPEUTICS INC | $0 | – | -52,051 | -100.0% | -0.20% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -2,366,707 | -100.0% | -0.51% | – |
| UROV | Exit | UROVANT SCIENCES LTD | $0 | – | -102,657 | -100.0% | -0.54% | – |
| Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -12,300 | -100.0% | -0.55% | – | |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -587,626 | -100.0% | -1.28% | – |
| ADMA | Exit | ADMA BIOLOGICS INC | $0 | – | -548,409 | -100.0% | -1.35% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -41,700 | -100.0% | -1.48% | – |
| FIXX | Exit | HOMOLOGY MEDICINES INC | $0 | – | -153,303 | -100.0% | -1.54% | – |
| ABBV | Exit | ABBVIE INC | $0 | – | -39,000 | -100.0% | -1.64% | – |
| HUM | Exit | HUMANA INC | $0 | – | -12,000 | -100.0% | -1.70% | – |
| HNGR | Exit | HANGER INC | $0 | – | -395,000 | -100.0% | -4.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.